PathMaker Neurosystems: Building the Future of Neurotechnology

PathMaker Neurosystems is a clinical-stage neurotechnology company advancing a breakthrough treatment for ALS and other serious neurological disorders by suppressing motor neuron hyperexcitability. The company's vision is to "make ALS a livable disease" by restoring damaged neural pathways through its proprietary technology.

After relocating from Boston to Point225 in Providence's 195 District, PathMaker received a 2025 business attraction grant from the Rhode Island Life Science Hub, reinforcing the state's commitment to growing its life sciences sector. The company has already hired its first Rhode Island employee, a recent University of Rhode Island graduate with a Ph.D. in neuroscience.

"We can feel the energy here," the company noted. "Moving from Boston to Providence's 195 District made sense given the proximity to top neuroscience research institutions, clinical partners, and the growing life sciences ecosystem. The move accelerates our ability to advance transformative treatments while giving us access to the talent, collaboration, and innovation that directly support our mission to bring breakthrough therapies to market."